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Synapse loss is associated with motor and cognitive decline
in multiple neurodegenerative disorders, and the cellular
redistribution of tau is related to synaptic impairment in tauo-
pathies, such as Alzheimer’s disease and frontotemporal de-
mentia. Here, we examined the cellular distribution of tau
protein species in human tau overexpressing line 66 mice, a
transgenic mouse model akin to genetic variants of frontotem-
poral dementia. Line 66 mice express intracellular tau aggre-
gates in multiple brain regions and exhibit sensorimotor and
motor learning deficiencies. Using a series of anti-tau anti-
bodies, we observed, histologically, that nonphosphorylated
transgenic human tau is enriched in synapses, whereas phos-
phorylated tau accumulates predominantly in cell bodies and
axons. Subcellular fractionation confirmed that human tau is
highly enriched in insoluble cytosolic and synaptosomal frac-
tions, whereas endogenous mouse tau is virtually absent from
synapses. Cytosolic tau was resistant to solubilization with
urea and Triton X-100, indicating the formation of larger tau
aggregates. By contrast, synaptic tau was partially soluble after
Triton X-100 treatment and most likely represents aggregates
of smaller size. MS corroborated that synaptosomal tau is
nonphosphorylated. Tau enriched in the synapse of line 66
mice, therefore, appears to be in an oligomeric and nonphos-
phorylated state, and one that could have a direct impact on
cognitive function.
Tau proteins belong to the microtubule-associated protein
(MAP) family. They play an important role in the assembly of
tubulin monomers into microtubules, which constitute the
neuronal microtubule network (1). In the 1970s, the microtu-
bule-associated protein tau was identified as a polymerization
factor for microtubules, which promotes microtubule assembly
and provides axonal stabilization (2). Fragmented tau proteins
constitute the major components of intra-neuronal lesions,
paired helical filaments (PHFs) characteristic of Alzheimer’s
disease (AD) brain (3) and other tau-related neurodegenerative
disorders referred to as “tauopathies” (4). The human tau gene
(MAPT) is encoded on chromosome 17 and alternative splicing
of exons 2, 3, and 10 of the primary transcript leads to expres-
sion of 6 tau isoforms in the central nervous system (CNS) (5).
N-terminal projection domains of tau isoforms contain 0, 1, or
2 inserts, and these determine the spacing between microtu-
bules and the diameter of axons (6, 7). The C-terminal microtu-
bule-binding domains contain either 3 or 4 tandem-repeat
domains (R1–R4) that serve as regions that interact withmicro-
tubules (8, 9). In addition to their role in promoting microtu-
bule stability and organization, tau may also be involved in the
regulation of axonal guided transport through interactions
with motor proteins and other binding partners (for review see
Ref. 10).
In the longest humanCNS tau isoform of 441 amino acid res-
idues, more than 85 putative phosphorylation sites have been
reported, most of which are located near themicrotubule-bind-
ing repeat domains (11, 12). Phosphorylation of tau modulates
its affinity to microtubules and multiple kinases and phospha-
tases regulate tau phosphorylation (10, 13–15). Hyperphos-
phorylation inhibits tau–tubulin binding (16, 17) and has been
proposed as being important for tauopathies (18, 19). Other
factors, such as glycosylation, caspases, and chaperones may
also affect both microtubule assembly and tau aggregation (19,
20). Nevertheless, the relevance of tau phosphorylation in dis-
ease progression is uncertain. Phosphorylation of tau inhibits
tau–tau binding and is preceded by aggregation of nonphos-
phorylated tau (16, 17) and the aggregation of nonphosphory-
lated tau is correlated with the onset of cognitive impairment in
mice (21).
Irrespective of its phosphorylation state, high affinity binding
through the repeat domain (16) and aggregation of truncated tau
to form PHFs (22) can be shown to occur in vitro in the absence of
phosphorylation. Tau aggregation appears to compromise presyn-
aptic releasemechanisms, but has little effect on baseline functions
of the post-synaptic and hippocampal pyramidal cells (23) and
squid axon (24). These data suggest that tau, in addition to its path-
ogenic role in axons (25, 26), accumulates in dendrites and synap-
ses (27, 28), where it can promote actin polymerization to cross-
link with synaptic vesicles, thus restricting their mobilization and
lowering neurotransmitter release (29). These data strengthen the
view that different tau protein pools may be compartmentalized
into various cell spaces, which may be functionally distinct. Both
pre- and post-synaptic tau colocalizeswith compartment-specific
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biomarkers in humanAD brain (30–33) indicating that better
characterization of the different tau species in these com-
partments would enable a better understanding of the mis-
sorting mechanisms that operate (34, 35). This was exam-
ined in our line 66 (L66) mouse as a prototype tauopathy
model mimicking frontotemporal dementia (FTD) with par-
kinsonism overexpressing full-length human tau including
mutations P301S and G335D (21).
The focus in this study was on functionally distinct cell com-
partments, e.g. the cytosol and the synapse. In mice, axonal
localization of normal tau was confirmed (36, 37), but mislocal-
ization of tau might mediate its pathological propensity (38)
with different effects on cell function. Because synapse loss
is a good correlate for cognitive capacity in AD (39), we
explored how tau localization is affected in these transgenic
mice. We report that mutant human tau forms aggregates
that do not incorporate endogenous mouse tau and that non-
phosphorylated, insoluble human tau protein is enriched in
synapses, whereas tau species found in axons and soma are
phosphorylated.
Results
We here characterized the cellular compartmentalization of
tau protein species in L66 transgenic mice that express full-
length mutant human (htau40 with P301S and G335D muta-
tions) under the control of the Thy1-regulatory element with
an early onset and widely distributed tau pathology.We applied
a range of tau antibodies (Fig. 1 and Table 1) to explore (a)
whether different aggregation products of the transgenic
human tau are compartmentalized, and (b) whether the phos-
phorylation state differs between compartments within the
same neurons (i.e. soma, cytosol, synapse). Initial immunohis-
tochemical findings were then explored and corroborated
through subcellular biochemical fractionation.
Figure 1. Schematic representation of epitopes of anti-tau antibodies. The epitopes recognized by the different anti-tau antibodies used in this work are
indicated with numbering based on the longest human CNS tau isoform (2N4R; 441 amino acids). Detailed description of antibodies, including IgG class and
supplier are listed in Table 1.
Table 1
Description of antibodies used in this study, including dilutions used for immunohistochemistry (IHC), immunofluorescence (IF), and immu-
noblotting (IB)
Antibodya Species/class Immunogen Epitope Supplier (Reference) Product
Dilution
IHC IF IB
mAb 7/51 Mouse IgG1k PHF-tau Tau 350-368 TauRx Therapeutics (88) 7/51 1:2,000 NAb 1:100




#4019 1:2,000 NA 1:2,000
mAb 27/499 Mouse IgG2bk 2N4R tau Tau 14-26 TauRx Therapeutics (79) 27/499 1:200 NA NA
mAb HT7 Mouse IgG1k Purified human tau Tau 159-163 Thermo Scientific (90) MN1000 1:5,000 1:5,000 1:2,000
pAb pSer-202-tau Rabbit IgG Synthetic peptide
corresponding to
residues surrounding
Ser-202 of human tau
protein
Tau pSer-202 Cell Signaling (91) #11834 1:500 1:500. NA
mAb pSer-396-tau Mouse IgG2b Purified human tau Tau pSer-396 Cell Signaling (92) #9632 1:2,000 1:2,000 NA
mAb pSer-416-tau Rabbit IgG Synthetic phosphopeptide
corresponding to
residues surrounding
Ser-416 of human Tau
protein
Tau pSer-416 Cell Signaling (93) #15013 1:500 1:500 NA
pAb b-actin (C-11) Goat IgG b-actin Actin carboxyl-
terminus
Santa Cruz Biotechnology sc-1615 NA NA 1:1,000
mAb synapsin-1 Mouse IgG1k Synapsin-1a and 1b Synapsin 1 proline-
rich D domain
Synaptic Systems (94) 106001 NA 1:2,000 1:10,000
mAb synapsin-2 Rabbit IgG hSynapsin-2 Synapsin-2 Gly-503 Cell Signaling #85852 NA 1:2,000 NA




NA Biolegend (95) #MMS-614P NA NA 1:1,000
mAb syntaxin Mouse IgG1 Crude synaptic prep-
aration from the human
post-mortem brain
Syntaxin 4-190 Abcam ab112198 NA NA 1:20,000
mAb PSD95 Rabbit IgG hPSD95 PSD95 Gln-53 Cell Signaling (96) #3450 NA NA 1:500
amAb, monoclonal antibody; pAb, polyclonal antibody.
bNA, not applicable for this study.
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Histopathological confirmation of hTau in all neuronal
compartments
We first established histologically that transgenic human tau
accumulates in cell bodies, dendrites, and synapses in L66 mice
(Fig. 2 and Fig. S1). Immunopositive labeling was confirmed for
all antibodies in cortex, striatum, and hippocampus of L66,
whereas sections from WT controls were devoid of tau immu-
noreactivity with the panel of antibodies we have used spanning
a number of domains across the tau molecule (Fig. 1). Labeling
with phosphorylation-independent tau antibodies 7/51 (Fig.
2A), Tau46 (Fig. 2B), and HT7 (Fig. 2C) was observed in the
somata of pyramidal cells in CA1, hilus of the dentate gyrus,
ERC (entorhinal cortex) and cortex (see black arrowheads, Fig.
2), but also in cortical and hippocampal dendrites (Fig. 2, white
arrowheads) and in nerve terminals in cortex and striatum (Fig.
2C, circles). Human-specific N-terminal tau mAb 27/499 (Fig.
2D) showed a similar pattern of labeling. The pattern of labeling
seen with phosphorylation-dependent antibodies was distinct.
Immunoreactivity for pSer-202 (Fig. 2E), pSer-396 (Fig. 2F),
and pSer-416 (Fig. 2G) were seen mainly in cell bodies and
axons of principal cells in cortex, the hilus, and CA1, but not in
nerve terminals.
Tau accumulation in synapses was verified by double labeling
of sections with HT7 (mouse) and the synaptic protein synap-
sin-2 (rabbit). Because synapsin-1 (used for biochemical assays,
see below) and synapsin-2 are distributed similarly within the
pre-synapse (40), synpasin-2 was used for double labeling as it
was the only synapsin antibody available not raised in mouse.
Tau recognized by HT7 was found to be co-localized with syn-
apsin-2, confirming its synaptic localization (Fig. 3). Synaptic
tau was seen mainly in striatum, cortex, and stratum radiatum
of CA1, but was absent in other hippocampal regions. Phos-
pho-tau was virtually absent from synapses (Fig. S2). These
data confirm that transgenic mutant human tau is present in all
compartments of the neuron with some region-specific varia-
tion in labeling in synaptic endings.
Subcellular fractionation confirms hTau in all compartments
of L66 neurons
To characterize better the compartmental localization of
human tau in L66 mice, we next applied ultracentrifugation
and subcellular fractionation of brain extracts. The procedure
for generating the fractions is depicted in Fig. 4. Importantly,
P1 and P3 are pellets derived from the soma of cells, whereas P2
is a crude synaptosomal fraction. Further centrifugations of P2
produced LP1 (a mix of pre- and post-synaptic compartments)
and LP2 as the enriched synaptic fraction. The cytosol is repre-
sented by fractions S1–S3. The LS1 fraction was used as a refer-
ence for quantitative comparisons as it had the lowest levels of
the proteins of interest (relative protein level (RPL) equals 1).
Synaptic enrichment in fractions LP1 and LP2was confirmed
by enrichment of synapsin-1 and PSD95 proteins (Fig. 5, A–D).
As expected, synapsin-1 was highly enriched in all pellet frac-
tions (Fig. 5, A and B; for quantification see Figs. 6A and 7A) in
both WT controls and L66 tissue. Consistent with a previous
report (41), the most highly purified synaptic vesicle fraction
LP2 and the pre- and postsynaptic membrane fraction LP1 had
40- to 60-fold enrichment of synapsin-1 compared with LS1.
PSD95 was found mainly in pellets P1, P2, and in the pre- and
postsynaptic membrane fraction LP1 (Fig. 5, C and D, and Figs.
6B and 7B for quantification) as reported by others (34, 42).
Murine tau was quantified using mAb Tau46 (Fig. 5, E and F,
white arrowheads). Although this antibody labels tau in both
WT and L66 brain preparations, murine tau has a gel mobility
of 50-55 kDa. There was a 10- to 15-fold enrichment of murine
tau in the crude pellet fractions P1 and P3 (quantification in
Figs. 6C and 7C). There was relatively little enrichment of the
50-55–kDamurine tau in LP1 (3.5-fold) and LP2 (2-fold).
Figure 2. Tau immunohistochemistry in L66 andWT controlmice. Tau im-
munoreactivity with phosphorylation-independent antibodies 7/51 (A),
Tau46 (B), HT7 (C), and 27/499 (D), andwith phosphorylation-specific antibod-
ies pSer-202 (E), pSer-396 (F), and pSer-416 (G) show prominent intraneuronal
staining in cortex and hippocampus in L66 brains. Phosphorylation-inde-
pendent antibodies showed strong synaptic staining mainly in striatum
in L66 (A–D). Phosphorylation-specific antibodies showed strong staining in
cell bodies and axons in L66 (E–G). Black arrowhead, cytosolic staining in
neurons; white arrowhead, axonal/dendritic staining; circle, synaptic stain-
ing. CA1, hippocampus subfield CA1; STRI, striatum. Scale bars, 100 mm. L66,
line 66 tau transgenic mice.
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Transgenic mutant tau has a distinct gel mobility of 62 kDa,
which could be detected using phosphorylation-independent
antibodies 7/51, HT7, and Tau46 (Fig. 5, E–J, black arrow-
heads) and this was seen only in brain tissues from L66 mice
and not inWT samples. Transgenic 62-kDa tau was detected in
all pellet fractions with antibodies 7/51 (Fig. 7D, 10- to 15-fold),
as well as with HT7 and Tau46 (Fig. 7, E and F, 3- to 6-fold). Of
particular interest, the co-purification of the 62-kDa human
tau with synaptic proteins in the synaptic LP1 and LP2 fractions
corroborates the co-localization established by immunohisto-
chemistry (Fig. 3).
Synaptic hTau in L66 is nonphosphorylated
We further explored the phosphorylation status of human
and murine tau using MS. This approach was necessary given
the large number of phosphorylation sites of tau that have been
reported and the limited amounts of tau protein available from
LP1 and LP2. Application of MS has the further advantage that
it can detect the presence of multiple phosphorylation sites in a
single sample run. The 62-kDa tau bands specific to L66 found
in the various subcellular extracts (Fig. 5J) were excised from
silver-stained gels and subjected to Orbitrap LC–MS. Bands
were taken in duplicates and digested with either trypsin or
thermolysin to increase sequence coverage.
Transgenicmutant human tau was found in all nine fractions
(Table 2 and Table S1 and Figs. S3–S7 for detailed MS data)
corroborating the results from immunoblotting (Fig. 5). With
the PEAKS software, we established phosphorylation of trans-
genic tau at Thr-181, Ser-199, Ser-202, and Thr-231 (Table 2
and details in Table S2 and Figs. S3–S7 ) in fractions S1, S2, S3,
and LP1. Of particular interest, no phosphorylated residues
were identified in fractions LS1, LS2, and LP2. Because these
represent the subfractions derived from the crude P2 synapto-
somal preparation, this implies that the transgenic human tau
found in synapses was not phosphorylated in any of the peptide
fragments that were analyzed.
Urea resistance of large hTau aggregates
Given that transgenic mutant human tau differs from native
murine tau in terms of compartment distribution and phos-
phorylation status, we sought to understand better the differen-
ces in solubility in 7 M urea, which disrupts membrane interac-
tions and hydrogen bonding (Fig. 8). Tau with 62-kDa gel
mobility detected with mAb 7/51 was found in approximately
equivalent amounts in the urea supernatant and pellet fractions
after low-speed centrifugation (16,0003 g for 45 min). The lev-
els in L66 mice were 4-fold higher in both fractions relative to
the 55-kDa murine tau released into the urea supernatant (Fig.
8A, black and white arrowheads, respectively, and Fig. 8B for
quantification). By contrast, murine tau was found at a lower
level in the urea supernatant from WT mice compared with
L66 mice and was largely absent from urea pellet in WT mice
(Fig. 8B, 1 to 2-fold).
Mutant hTau is partially insoluble in Triton X-100
We used differential centrifugation in the presence or ab-
sence of Triton X-100 to compare the distribution of mutant
human tau and native murine tau using mAb 7/51 in immuno-
blots (Fig. 9). As noted above, the 62-kDa tau species was absent
in specimens from WT mouse brain, whereas murine tau spe-
cies with gel mobility in the 50–55 kDa range were present in
both L66 and WT specimens. The amounts of 55-kDa tau in
the low-speed pellet and supernatant fractions were compara-
ble. Following high-speed centrifugation of the low-speed su-
pernatant, the amounts of 55-kDa tau were again comparable
in the high-speed supernatant (FS) and pellet (FP) fractions
Figure 3. Synaptic localization of tau in L66 using immunofluorescence.
Tau immunoreactivity with the phosphorylation-independent antibody HT7
is localized in the neuronal soma (arrows), dendrites, and axons of neurons in
hippocampal CA1 and CA3, cortex and hilus of the dentate gyrus. Co-localiza-
tion of HT7-reactive tau and the synaptic marker synapsin-2, seen as yellow
puncta in the merged images (double arrowhead), confirms the synaptic
accumulation of transgenic tau. Synaptic staining of tau is evident mainly in
striatum and, to a lesser extent, in cortex and stratum radiatum of the CA1.
Green, tau; red, synapsin-2. Arrow, staining in the neuronal soma; double
arrowhead, synaptic staining. Scale bars, 25mm.
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prepared from L66 and WT mice, with the levels in the pellet
approximately double those in the supernatant (Fig. 9F).
When the same procedure was carried out in the presence of
Triton X-100 the amounts in the pellet from L66 and WT
mice were both substantially reduced in the high-speed pellet
(Fig. 9G).
Compared with the level of 55-kDa tau in the low-speed pel-
let, there was 2-fold enrichment of 62-kDa tau in the same pel-
let and 1.3-fold enrichment in the corresponding supernatant
from L66 mice (Fig. 9D). Following high-speed centrifugation
of the supernatant, the majority of the 62-kDa tau was in the
pellet (1.3-fold enrichment) with little remaining in the super-
natant (0.4-fold RPL). This distribution was reversed when the
same procedure was carried out in the presence of Triton X-
100, with the majority now in the high-speed supernatant (1.2-
fold), but with a 0.5-fold RPL remaining in the pellet (Fig. 9E).
Therefore, approximately half of the 62-kDa tau from L66 mice
is resistant to solubilization by Triton X-100. Because Triton
X-100 would be expected to solubilize any membrane com-
plexes, we interpret this as indicating that the 62-kDa tau sedi-
menting in these conditions is in the form of oligomeric com-
plexes of molecular mass of at least 500 kDa. Similar findings
were seen using HT7 (data not shown).
Soluble hTau is stable to heat denaturation
We further compared the heat stability of mutant human
and native murine tau species isolated from the low-speed su-
pernatant in brain extracts from L66 and WT mice. As seen in
Figure 4. Extraction protocol for subcellular fractionation. Brain tissue homogenate was centrifuged at speeds as indicated in the diagram to allow separa-
tion of synaptic from cellular fractions.
Figure 5. Cellular distribution of tau using subcellular fractionation. Brain tissue fromWT controls (left panel) and L66 (right panel) were subjected to sub-
cellular fractionation as described under “Experimental procedures.” Sample fractions (1 mg of total protein) were separated on 4–20% gradient glycine-SDS-
PAGE and representative immunoblots are shown. Antibodies against synapsin-1 and PSD95 (A–D) were used to confirm synaptic enrichment. Antibodies
against tau (E and F for Tau46, G and H for 7/51, and I and J for HT7) were used to quantify tau in the different fractions. Transgenic tau, reactive with 7/51 and
HT7 was evident in most fractions of L66 mice, visible as a 62-kDa band (black arrowheads), whereas no specific signal for WT mice was seen using either anti-
body. A tau band at around 50-55 kDa (white arrowheads), reactive with the antibody Tau46, showed a similar enrichment pattern for endogenous tau, both in
WT controls (E) and L66 (F). Black arrowheads, 62-kDa band, specific to L66 tau-transgenicmice.White arrowheads, 50-55-kDa band, murine tau. L66, line 66 tau
transgenic mice. All 10 bands corresponding to transgenic tau from different fractions were excised from silver-stained glycine gels for downstreamMS analy-
ses and results are shown in Table 2 and Tables S1 and S2.
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Fig. 10, there is substantial selective enrichment of the 62-kDa
tau species in the supernatant following heat treatment for 5 or
30 min at 95˚C. There is minimal corresponding enrichment of
native murine tau. The results were similar for both phospho-
rylation-independent antibodies 7/51 and HT7 (Fig. 10A, black
arrowheads). The enrichment of human tau was more than 10-
fold compared with that present in the low-speed supernatant
(Fig. 10, B and C). By contrast, b-actin, synapsin-1, PSD95, and
syntaxin were completely absent from the heat-stable superna-
tant (HS) after only 5 min of heat treatment (Fig. 10A); the
same was the case for synaptophysin and synapsin-2 (data not
shown), whereas SNAP25 showed some resistance toward
treatment with heat. Therefore, unlike transgenic tau, other
membrane-interacting and synaptic proteins are not resistant
to heat denaturation.
Discussion
L66 mice overexpress the longest human CNS tau isoform of
441 amino acid residues, which contains the aggregation-pro-
moting mutations P301S and G335D. Expression of mutant
human tau is widespread in the brain in this model producing
prominent tau aggregates in neurons that can be labeled with
Bielschowsky silver and primulin (21). We have now extended
the studies in L66 with the aim of understanding better the dif-
ferential compartmental localization of full-length native
mouse and transgenic mutant human tau and how the phos-
phorylation status of mutant tau varies according to its com-
partmental localization within neurons. The key novel findings
that we report are that although mutant human tau appears to
have a wide distribution by immunohistochemistry, biochemi-
cal analysis reveals that its compartment distribution differs in
a number of respects from that of native tau. Whereas native
tau is largely soluble in urea and detergent, a substantial pro-
portion of mutant tau in the brain is insoluble in both. Of par-
ticular interest, we report that mutant tau is co-localized with
synaptic markers histologically and co-purifies with synaptic
proteins in synaptosomal and synaptic vesicle preparations. Im-
munoblotting and sequence analysis of peptide digests of syn-
aptic mutant tau reveal that it is largely unphosphorylated,
whereas it is phosphorylated in cell body and axons (summar-
ized in Table 3). Therefore, the differential neuronal processing
of mutant human tau relative to native murine tau, particularly
in synapses, may underlie its adverse effects on behavior.
Two basic features have made it possible to differentiate
native mouse tau from mutant human tau in the brain. At the
histological level, there is no labeling of native tau inWTmouse
brain with any of the monoclonal antibodies we have used
spanning N-terminal, repeat domain and C-terminal segments
of the molecule under the conditions we have used. This is a
well-recognized immunohistochemical feature of native tau
using conventional tissue processing with formalin fixation
(43). By contrast, transgenic mutant tau can be labeled by
all the antibodies we have tested, including both phosphoryla-
tion-dependent and phosphorylation-independent monoclonal
antibodies. Although the reasons for this difference are not yet
fully understood at the molecular level, they indicate that the
endogenous processing and consequent epitope exposure of
mutant tau is fundamentally different from that of native tau.
The biochemical characterization of these differences is made
possible by the difference in gel mobility between native mouse
and transgenic human tau in immunoblots. Most forms of tau
protein are well-known to have atypical gel mobility relative to
their molecular weight. This has been shown to be due to
altered affinity for SDS, which has the effect of retarding their
electrophoretic mobility in gels (5, 44). In particular, mouse tau
has gel mobility corresponding approximately to 50-55 kDa,
whereas mutant human tau has gel mobility corresponding to
;62 kDa. This makes it possible to distinguish the two forms of
tau in immunoblots despite using monoclonal antibodies,
which are not inherently discriminatory.
We first show that mutant human tau co-localizes immuno-
histochemically with synapsin-2. This was seen mainly in stria-
tum, and to a lesser extent in cortex and stratum radiatum of
CA1. We then used biochemical fractionation to determine
whether mutant tau co-purifies with pre- and post-synaptic
markers (synapsin-1 and PSD95, respectively). Synaptic pro-
teins were found in crude fractions pelleting with sedimenta-
tion limits corresponding to a particle of size 95 nm (crude syn-
aptosomal fraction P2 and the LP1 fraction containing pre- and
post-synaptic membranes). These were further enriched in the
preparations with particle sedimentation limits corresponding
to 21 nm (microsomal fraction P3) and 15 nm (synaptic vesicle
fraction LP2). Mutant tau protein recognized by the repeat-do-
main marker (mAb 7/51; residues 350-368) was found to be
enriched in the smallest particle fractions P3 (21 nm) and LP2
(15 nm). The same was true to a somewhat lesser extent using
more N-terminal (HT7; residues 159-163) and C-terminal
(Tau46; residues 404-441) antibodies. Sequencing of peptides
from the 62-kDa tau protein co-purifying with synapsin-1 in
Figure 6. Quantification of synaptic markers and tau after subcellular
fractionation in WT mice. Densitometric quantification of synapsin-1 (A),
PSD95 (B), and Tau-46 reactive mouse tau at 50-55 kDa (C) was conducted
with Image Laboratory using stain-free total protein loading for normaliza-
tion. Data are expressed asmean6 S.E.
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these fractions identified tau fragments spanning residues 195
to 369 by MS sequence analysis. Although small amounts of
native mouse tau were also identified in these fractions, these
were present at levels;20% of the levels of mutant human tau.
Therefore, we have established that soluble tau species from
mutant human tau co-localize with synapses and co-purify
with synaptic proteins in crude synaptosomal and enriched
synaptic vesicle extracts in the L66model of FTD.
When the phosphorylation status of transgenic human tau
was examined further, we found that none of the phosphoryla-
tion-dependent monoclonal antibodies co-labeled with synap-
ses. The labeling seen with these antibodies was restricted
mainly to the cell bodies and axons of principal cells in cortex
and hilus and CA1 of hippocampus. This was confirmed bio-
chemically. Phosphorylated transgenic tau was found predomi-
nantly in low-speed supernatant fractions and remained in the
supernatant following high-speed centrifugation. This was con-
firmed by MS sequence analysis, which identified peptides
phosphorylated at Thr-181, Ser-199, Ser-202, and Thr-231 in
these fractions. Of particular note, none of the peptides isolated
from transgenic tau and co-purifying with synapsin-1 was
found to be phosphorylated. The only exception to this was in
the fraction containing crude synaptosomal constituents that
sedimented with particles of size greater than 95 nm.We there-
fore conclude that the transgenic mutant human tau that accu-
mulates in synapses is predominantly unphosphorylated. This
protein sediments as a particle having a molecular mass of at
least 200 kDa corresponding to trimeric or larger, low-order
oligomers. By contrast, the aggregated tau protein found in cell
bodies is largely filamentous and is found in the higher order
tangle-like structures that can be labeled with Bielschowsky sil-
ver and primulin. Having this information, further immunoe-
lectron microscopy studies may reveal more detail on the pro-
cess of oligomer and filament assembly within the neuron and,
particularly at the synapse.
Consistent with our findings, an association between mutant
tau and synaptic vesicles has been reported previously in both
Drosophila and rat neurons (23, 29). These vesicle-tau interac-
tions hamper transmitter release through polymerization of N-
terminal tau domains linking presynaptic F-actin with vesicle
membranes, thereby making the presynaptic compartment
more rigid (29). That the respective tau species destined for the
presynaptic compartment can be oligomeric and nonphos-
phorylated was established by micropipette administration of
tau through the patch pipette while recording from affected
cells in the whole cell configuration (23). Voltage recordings
revealed strongly reduced action potential amplitudes and
slowed action potential rise and decay kinetics. Pre-synapti-
cally, tau increased the run-down or unitary responses suggest-
ing either reduced availability of vesicular release (29) or
Figure 7. Quantification of synaptic markers and tau after subcellular fractionation in L66 mice. Densitometric quantification of synapsin-1 (A), PSD95
(B), Tau-46 reactive mouse tau at 50-55 kDa (C), as well as transgenic human tau at 62 kDa reactive with 7/51 (D), HT7 (E), and Tau-46 (F) was conducted with
Image Laboratory using stain-free total protein loading for normalization. Data are expressed asmean6 S.E.
Table 2
Subcellular fractions (see Fig. 4 for fractions) probed by Orbitrap LC-MS and identified by Mascot and PEAKS search engines
Phosphorylated tau peptides were identified by PEAKS. Only the transgenic human tau isoform Tau-X is shown. For detailed MS results, see Tables S1 and S2.
Subcellular Fraction Number of peptides matched (Mascot/PEAKS) Number of phosphorylated peptides Phosphorylation sites
S1 18/21 4 Thr-181, Ser-202, Thr-231
P2 4/5 None -
S2 17/28 6 Thr-181, Ser-199, Ser-202, Thr-231
P3 14/14 None -
S3 16/22 4 Thr-181, Thr-231
LP1 13/20 4 Thr-181, Ser-202, Thr-231
LS1 6/6 None -
LP2 3/2 None -
LS2 1/1 None -
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lowered re-uptake of transmitter in synaptic vesicles due to in-
hibition of P-type Ca21-ATPases by tau (45, 46). At physiologi-
cal pH and under challenge, these Ca21 ATPases promote
Ca21/H1 exchange activity at the vesicular membrane and
Ca21 uptake into the vesicle (47). Neighboring cells were not
affected by this treatment. Furthermore, transfection of full-
length tau into neurons was associated with decreased expres-
sion of synaptic markers and reduced transport of these
proteins into the presynapse (48), as well as with Ca21 dysregu-
lation (49). An association between vesicles and actin promoted
through the N-terminal domain of tau (29) could contribute
both to the insolubility of tau and increased rigidity in the syn-
aptosomal compartment. Accumulation of tau in the cytoplasm
is thought to interfere with a range of normal physiological
processes (for review see Ref. 50). The accumulation of tau
aggregates in the cytosol in L66 mice was a feature also
observed in JNPL3 mice (P301L mutation). As in our L66
model, the overexpressed mutant tau led to the formation of
cytoplasmic tau aggregates, neuronal loss, and motor deficits
(21, 51, 52), and is consistent with what is observed in tauopa-
thies (for review see Ref. 53).
That soluble tau species can modulate the post-synaptic
compartment was suggested through the administration of in-
tracerebroventricular recombinant or AD tau aggregates (38,
54). These investigators reported deficits in hippocampal long-
term potentiation, but no deficits in paired pulse inhibition
ratios. This is in line with our labeling of tau protein in fraction
LP1, which contained both presynaptic (synapsin) and post-
synaptic elements (PSD95). As is confirmed here for L66, these
tau species are in both phosphorylated and nonphosphorylated
states and require the C-terminal domain of the tau molecule
(55). Some of the phosphorylation sites identified in L66 mice
were also seen in WT control mice and have also been
described in postmortem brain tissue of cognitively normal
people, suggesting the existence of selective phosphorylation
states under physiological conditions (12, 56) and are likely not
related to pathological processing of tau.
The cellular distribution of different tau pools might be
attributed to specific localization-dependent post-transcrip-
tional regulation events. For example, several kinases have been
described that phosphorylate tau (13, 14, 57). In addition, it has
been reported that both phosphatases and kinases are also
compartmentalized, and that synaptic phosphorylation acti-
vates a number of proteins (for review see Refs. 58 and 59).
Therefore, it seems likely that tau undergoes compartment-
specific modification and aggregation processes. A brain
region-specific increase in phospho-tau-positive synapto-
somes in AD patients has been reported using crude cortical
synaptosomal preparations (30), similar to our MS findings in
the crude P2 and LP1 factions from L66 brain tissues. Others
have also reported that synaptic tau extracted from AD brain
tissues is oligomeric and hyperphosphorylated (30, 31) but
this has not been confirmed. Sokolow and colleagues (33) la-
beled the majority of synaptic terminals with HT7 (not spe-
cific for phosphorylated tau) in both AD and control subjects
and found an increase in a truncated 20-kDa tau fragment
lacking a C terminus and appearing as dimers in immuno-
blots from AD samples.
Mutant human tau was equally enriched in both supernatant
and pellet after addition of urea, whereas murine tau was
almost completely depleted in the urea pellet (summarized in
Table 4). The urea-resistant human tau species are less likely to
bemembrane bound, as urea disrupts these membrane associa-
tions and hydrogen bonding within tau protein aggregates (60).
Mouse tau is not insoluble in urea and remains in the superna-
tant. This is consistent with the observation in JNPL3 mice
expressing the P301L mutation (61). The sarkosyl-insoluble
preparation of tau in this model was found to be largely human
and only became filamentous in older animals. It appears that
the progression of tau aggregation pathology is more advanced
in our L66 mice to such an extent that the filamentous state
was already established at 7 months of age (21). In addition,
native mouse tau was largely absent from the high-speed Triton
X-100 pellet, supporting its inability to assemble into aggre-
gates. However, it is not possible to determine from the data
currently available whether there is some degree of recruitment
of mouse tau into the Triton- and urea-insoluble aggregates.
The mutant tau protein in the low-speed Triton X-100 super-
natant was found to remain heat stable even after lengthy expo-
sure to heat. It was also found to be stable when purified using
TCA (data not shown) (62). Heat stability is an inherent prop-
erty of tau as an aggregation-prone and intrinsically unstruc-
tured protein without a hydrophobic core (63–65) and is widely
used as a method for separation of tau from other abundant
proteins (2, 63, 64). In contrast to tau, other synaptic proteins
were not heat stable. Increasing concentrations of insoluble tau
have been reported to lead to formation of filamentous tau
aggregates in elderly transgenic P301L tau mice (66). Triton-
insoluble filamentous tau species enriched from P301S mice
have a greater seeding potential in vitro (67) and have higher
toxicity (68). However, we have reported recently that the
toxicity of filamentous tau can be dissociated from the ability
of truncated oligomers to induce abnormal phosphorylation
of endogenous tau (69). At present, the molecular mechanism
of aggregation of full-length mutant human tau remains
unknown.
Figure 8. Urea solubility of tau species. Brain tissue from L66 and WT con-
trol mice (n = 5 and 3, respectively) was subjected to urea protein extraction
and supernatant (S) and soluble pellet (P) fractions were obtained by low-
speed centrifugation (16,000 3 g for 45 min). Protein extracts (20 mg) were
separated on 10% Tricine-SDS-PAGE and the immunoreactivity of the frac-
tions was probed usingmAb 7/51 as shown in immunoblots (A). Densitomet-
ric quantification of the blots revealed 7/51-reactive tau specific to L66 (62-
kDa bands, black arrowhead) accumulated in P and S nearly to the same
extent, emphasizing that some of the transgenic tauwas resistant to urea sol-
ubilization (B). Murine tau detected at 55 kDa (white arrowhead) was almost
completely depleted from the pellet P after addition of urea. Densitometric
quantification was conducted with AlphaEase using the 55 kDa band in S
fromWT for normalization. Values are expressed asmean6 S.E.
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Although our data provide strong evidence that the mutant
human tau that aggregates in the synaptic compartment is non-
phosphorylated, this is at odds with some other reports. For
example, Kimura and co-workers (66) suggest that phosphoryl-
ation is crucial for the development of synaptic tau toxicity and
synapse loss in P301L mice. By contrast, Zhou et al. (29)
reported datamore in line with those reported here, confirming
that synaptic function is compromised using both pathogenic
human tau mutants and phosphomimetic tau species devoid of
14 putative phosphor-serine/threonine residues (changed to
glutamate residues). These data are consistent with evidence
showing that tau aggregation and toxicity can both occur in the
absence of any phosphorylation (16, 22, 69). Phosphorylation of
tau inhibits tau–tau binding (16, 17) and might play a protec-
tive role against its toxicity (17, 70–73). Consistent with this,
aggregation of nonphosphorylated tau correlates with the onset
and extent of cognitive impairment in mice (21) and humans
(74, 75), whereas phospho-tau pathology appears to be a late
stage event in the disease progression (74). It is not known at
present what triggers pathological compartmentalization of
tau and how specifically this affects synaptic membranes or
vesicles.
Althoughwe have gone someway toward defining the abnor-
mal compartmentalization of transgenic human tau in a mouse
model of FTD, there are important limitations in the work to
date. The tau protein accumulating in the core of the tau fila-
ments found in FTD brain tissues is restricted to the repeat
region similar to that found in the core of the PHF in AD (3, 76,
77), albeit with a different fold (78). This core is proteolytically
stable and propagates the aggregation cascade via a high affinity
tau–tau binding interaction (16, 79). The present study has
focused on the soluble transgenic mutant tau species that can
be isolated from mouse brain. The tau protein that remains in-
soluble after urea and/or Triton X-100 treatment needs to be
characterized further with a view to determining the identity of
any proteolytically stable and insoluble tau species generated in
this model. In L66 mice, the human tau is expressed in a form
that readily forms insoluble aggregates that do not incorporate
endogenous murine tau. Evidence for incorporation of endoge-
nous tau into tau aggregates in mice expressing different iso-
forms of human tau is variable. Although no co-aggregation
was seen in similar tau P301L mice (28, 61, 80), others have
reported such co-aggregation, e.g. in TauDK280 mice (81–84).
Further models, such as those expressing 3R isoforms, may dif-
fer and remain to be tested.
In summary, we here present an attempt to determine the
physicochemical changes of tau protein in different cellular
compartments in the L66 mouse model for FTD.We show that
transgenic mutant human tau form distinct insoluble aggre-
gates that do not incorporate endogenous mouse tau. The 62-
kDa human tau forms larger aggregates that are resistant to
urea and Triton X-100. Other species, oligomers of smaller size
that were sedimented at higher speed, were partially soluble af-
ter Triton X-100 treatment. The tau species that concentrate in
synapses are in a nonphosphorylated form. Another pool of tau,
which is in part Triton X-100–soluble, is heat stable, phospho-
rylated, and presumably cytosolic. Native mouse tau, on the
other hand, does not accumulate in synaptic fractions and is
neither urea/Triton X-100–resistant nor heat stable. The analy-
ses presented here for an FTD model, when compared with
physiologically appropriate AD models, will shed light on how
Figure 9. Tau protein solubility with and without Triton X-100. (A) Ex-
traction scheme for low- and high-speed extraction of brain tissue from L66
tau transgenic and WT control mice; tissue was subjected to extraction with
either Tris (B) or Tris-Triton X-100 (C). Pellet (P) and supernatant (S) fractions
were obtained by low-speed centrifugation at 16,000 3 g for 30 min,
whereas the fast pellet (FP) and the fast supernatant (FS) fractions were
obtained by high-speed centrifugation of S at 100,000 3 g for 1 h. Samples
(15 mg of protein) were separated by 10% tricine-SDS-PAGE and immuno-
blots are shown. The immunoreactivity of the fractions was probed using the
phosphorylation-independent anti-tau antibody 7/51. Densitometric quanti-
fication of the blots revealed 7/51-reactive tau (62-kDa bands) accumulated
in P, S, and FP fractions. After the addition of Triton X-100, some of 7/51-reac-
tive tau in FP fraction was solubilized and found in the FS fraction. Densito-
metric quantification was conducted with AlphaEase using the 55-kDa band
in P from WT for normalization. Values are expressed as mean 6 S.E. T, tau
ladder. Black arrowheads, 62-kDa human tau, and white arrowheads, 55-kDa
mouse tau. Gray arrows, 37-kDa band, non-tau nonspecific labeling.
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different tau conformations develop. This may help understand
the distinct pathologies observed for different tauopathies and
provide new therapeutic targets that may be either shared
between tauopathies or unique to individual disorders.
Experimental procedures
Animals
Tau transgenic L66 and NMRI WT control mice were used
in this study and have been described in detail previously
(21). L66 mice overexpress the longest human tau isoform
(2N4R) with 441 amino acid residues, under control of the
mouse Thy1-promoter. Two aggregation-promoting muta-
tions, P301S and G335D in the repeat domain, were inserted
into the tau cDNA and this mutated isoform is hereafter
termed Tau-X. Female homozygous transgenic L66 (n = 15)
andWT litters (n = 12) were bred commercially (Charles River
Laboratories, UK) in isolators and delivered by truck to Aber-
deen at least 10 days before experimental work commenced.
They were housed by genotype in small colonies up to 5 animals
in open housing (Macrolon III) with corncob bedding and paper
strips and cardboard tubes as enrichment (cleaning rota once
per week). Holding rooms were on constant temperature (20-22°
C), humidity (60–65%), and air exchange rate (17-20 changes/h)
with 12 h light/dark cycle (lights on at 6 am, simulated dawn).
Animals had free access to food and water and were aged 6-7
months when sacrificed by cervical dislocation. Brains were rap-
idly extracted and snap frozen in liquid nitrogen for protein stud-
ies or fixed for 24 h in formalin and embedded in paraffin for his-
topathology. There was no blinding or randomization at this
stage of the experiment. All animal experiments were performed
in accordance with the European Communities Council Direc-
tive (63/2010/EU) and a project license with local ethical ap-
proval under the UKAnimals (Scientific Procedures) Act (1986).
Brains were sent to Berlin via courier on dry ice.
Immunohistochemistry and immunofluorescence
Five-mm coronal sections were collected at desired brain
areas (corresponding to sections Bregma 23.8 mm for
Figure 10. Heat stability of Tris-soluble tau. Tris-soluble fractions (see Fig. 9, S fractions) were heated at 95 °C for 5 or 30 min and 2 mg of total protein of
original supernatant (S), the heat-stable supernatant (HS), and precipitated pellet fractions (HP) were subjected to 4–15% glycine SDS-PAGE and subsequent
immunoblotting using the phosphorylation-independent anti-tau antibodies 7/51 and HT7 as shown in representative immunoblots (A). With both antibod-
ies, heat-treated tau was mainly found in the supernatant fraction HS, and only a small subset of tau was found in the pellet HP. b-Actin and several synaptic
proteins were solely found in HP after only 5 min heat treatment. Dotted lines indicate where fractions from one brain were excised due to sample smearing.
The quantification in panels B and C represent data obtained from (A) and from further samples. Synapsin-1, PSD95, and syntaxin were not heat stable,
whereas SNAP25was partially stable toward heat treatment, as some of it remained soluble in the supernatant HS after 5min of boiling. Densitometric quanti-
fication for 7/51 (B) andHT7 (C) conductedwith Image Laboratory using stain-free total protein loading for normalization confirmed the findings for transgenic
tau, emphasizing the thermal stability of tau. Values are expressed asmean6 S.E. Black arrowheads, 62-kDa human tau.
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hippocampus and auditory/visual cortices and Bregma 10.74
mm for striatum and motor/entorhinal cortices of the mouse
brain atlas (85)) from randomly chosen L66 (n = 5) and WT
(n = 5) mice, de-waxed, boiled in 10 mM citrate buffer, and fur-
ther processed for immunohistochemistry or immunofluores-
cence as described below.
For immunohistochemistry, sections were boiled in 10 mM
citric buffer, incubated in hydrogen peroxidase solution (0.3%
(v/v)) for 10 min, and then for 20 min in blocking buffer (0.1%
(w/v) BSA in PBS). Sections were incubated in primary and sec-
ondary antibodies diluted in blocking buffer, each for 1 h at
room temperature with 33 10 min PBS-washing steps after
each antibody. Sections were developed with diaminobenzidine
solution (Dako, Denmark) and embedded in Neo-Mount®
(Merck Millipore, Germany). Anti-tau antibodies directed
against both phosphorylated and nonphosphorylated tau pro-
tein, and with epitopes in N- and C-terminal domains were
used: mAb 7/51, Tau46, HT7, mAb 27/499, pSer-202, pSer-
396, and pSer-416. The epitopes recognized by these antibodies
are illustrated in Fig. 1 and their details listed in Table 1.
For immunofluorescence, sections were blocked for 1 h in
blocking buffer (5% (v/v) normal goat serum in PBS containing
0.3% (v/v) Triton X-100) and incubated overnight at 4 °C in pri-
mary antibody mixture (HT7 and synapsin-2; pSer-202 and
Table 3
Summary for subcellular distribution of tau and its phosphorylation status using mmunohistochemistry, immunofluorescence, subcellular
fractionation and MS (see Figs. 2–6 and Table 2)
The following designations were used: S1-S3, LS1, LS2: supernatants; P1, nuclei and debris; P2, crude synaptosomes; P3, light membrane/microsomes; LP1, pre- and post-
synaptic membranes, LP2, synaptic vesicles.
Method Protein Antibody Genotype
Cellular compartment/fraction
Cell body Puncta
Immunohistochemistry Tau 7/51 L66 1 21
WT 2 1
HT7 L66 1 31
(co-localization with synapsin-2)
WT 2 2
Tau46 L66 1 21
WT 2 1
27/499 L66 1 2
WT 2 2
pSer-202 L66 1 1
WT 2 2
pSer-396 L66 1 1
WT 2 1
pSer-416 L66 1 1
WT 2 1
S1 P1 S2 S3 P3 P2 LS1 LP1 LS2 LP2
Subcellular fractionation Synaptic markers Syn1 L66 2 21 2 2 21 21 2 21 2 21
WT 2 21 2 2 21 21 2 21 2 21
PSD95 L66 2 21 2 2 2 21 2 21 2 2
WT 2 21 2 2 2 21 2 21 2 2
Human tau 7/51 L66 21 21 21 21 21 21 1 21 21 21
(62 kDa) WT 2 2 2 2 2 2 2 2 2 2
HT7 L66 21 21 21 21 21 21 1 21 21 21
WT 2 2 2 2 2 2 2 2 2 2
Tau46 L66 21 21 21 21 21 1 1 21 1 21
WT 2 2 2 2 2 2 2 2 2 2
Mouse tau Tau46 L66 2 21 2 2 21 2 2 1 2 1
(55 kDa) WT 2 21 2 2 21 1 2 1 2 1
MS Phosphorylated human tau Silver gel (62 kDa) L66 21 2 21 21 2 2 2 21 2 2
Table 4
Summary for urea/Triton X-100 solubility and heat stability of tau (see Figs. 7–9)
Experiment Antibody Tau Isoform Genotype P S FSa FP HP HS
Urea 7/51 Human tau (62 kDa) L66 21 21
WT 2 2
Mouse tau (55 kDa) L66 1 21
WT 1 21
Tris 7/51 Human tau (62 kDa) L66 21 21 1 21
WT 2 2 2 2
Mouse tau (55 kDa) L66 21 21 1 21
WT 21 21 1 21
Tris-Triton X-100 7/51 Human tau (62 kDa) L66 21 21 21 1
WT 2 2 2 2
Mouse tau (55 kDa) L66 21 1 1 1
WT 21 1 1 1
Heat stability 7/51 Human tau (62 kDa) L66 1 1 3+
WT 2 2 2
HT7 Human tau (62 kDa) L66 1 1 3+
WT 2 2 2
aEmpty cells, not applicable.
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synapsin-2, pSer-396 and synapsin-1 as well as pSer-416 and
synapsin-2, see Table 1 for dilutions) diluted in blocking buffer.
The next day, sections were washed 33 10 min with PBS, incu-
bated for 1.5 h in fluorochrome-conjugated secondary antibod-
ies (Alexa Fluor® 488-conjugated donkey anti-mouse IgG and
Alexa Fluor® 568-conjugated goat anti-rabbit IgG, Life Tech-
nologies, USA; both diluted 1:500 in blocking buffer), washed
again 33 10 min with PBS, covered with DAPI Gold Antifade
Reagent (Cell Signaling Technology, MA, USA), and examined
using a microscope equipped for fluorescence (Carl Zeiss, Jena,
Germany).
Subcellular fractionation of brain tissues
Subcellular fractionation was conducted as described before
(34) and the workflow is shown in Fig. 4. Randomly selected
brains from L66 (n = 5) andWT (n = 4) mice were used. Briefly,
10 volumes of Tris buffer (25 mM, pH 7.4) containing 9% su-
crose, 2 mM EDTA, 5 mM DTT and protease and phosphatase
inhibitors were added to crushed frozen brain tissues (pulver-
ized using a pestle and mortar with liquid nitrogen) and repeat-
edly pipetted up and down. The homogenate was centrifuged
for 5 min at 4 °C and 1,0003 g to obtain a supernatant (S1) and
pellet (P1, containing nuclei and large debris). S1 was centri-
fuged for 15 min at 4 °C and 12,5003 g to obtain a further su-
pernatant (S2, see below) and a crude synaptosomal fraction
pellet (P2). P2 was subsequently lysed in ice-cold water and the
lysate adjusted to 25 mM Tris and incubated for 30 min at 4 °C.
Thereafter, P2 was centrifuged at 25,0003 g for 20 min at 4 °C
to pellet a pre- and postsynaptic membrane fraction (LP1). The
supernatant fraction (LS1) was further centrifuged for 2 h at
4 °C and 176,0003 g to obtain a synaptic vesicle pellet fraction
(LP2) and a supernatant fraction (LS2). The S2 fraction from
above was centrifuged at 176,0003 g for 1 h at 4 °C to obtain a
cytosolic fraction (S3) and a light membrane/microsome-
enriched pellet fraction (P3). The pellets (P1, P3, LP1, and LP2)
were each suspended in 1 volume of reducing Laemmli buffer
(125 mM Tris-HCl, pH 7.0, 0.8% (w/v) SDS, 20% (v/v) glycerol,
and 10% (v/v) 2-mercaptoethanol). Protein concentration was
determined using the Bradford reagent (Carl Roth, Karlsruhe,
Germany), according to themanufacturer's recommendations.
Protein extraction from brain tissue using urea
Crushed frozen brain tissue from L66 (n = 5) andWT (n = 3)
mice was incubated for 45 min at room temperature in 6 vol-
umes of urea extraction buffer (7 M urea, 2 M thiourea, 2%
ampholyte 2-4, 70 mM DTT, 25 mM Tris/HCl, pH 8.0, 50 mM
KCl, 3 mM EDTA, 2.9 mM benzamidine, and 2.1 mM leupeptin)
and separated by centrifugation at 16,000 3 g for 45 min at
room temperature. The supernatant (S) was transferred to new
tubes. The pellet was mixed with 1 volume of reducing
Laemmli buffer, boiled for 5 min at 95 °C, and the soluble pellet
(P) was retained for later analysis. Both S and P fractions were
used for tau characterization. The protein concentration of all
fractions was determined as stated above.
Protein extraction from brain tissue with and without
detergent
Five volumes of Tris extraction buffer (30 mM Tris, pH 7.4,
containing cOmpleteTM protease inhibitor and PhosStopTM
phosphatase inhibitor mixture tablets from Roche), with or
without the addition of Triton X-100 (0.1% (v/v)), were added
to crushed frozen tissue (5 L66 and 3 WT brains pulverized
using pestle and mortar with liquid nitrogen), repeatedly pipet-
ted up and down for homogenization and incubated for 30 min
at 4 °C. The extraction procedure is shown in Fig. 9A. The ho-
mogenate was centrifuged for 30 min at 16,000 3 g and 4 °C.
The supernatant (S) was transferred to a new tube and the pel-
let (P) suspended in 1 volume of reducing Laemmli buffer.
Some of the supernatant (S) was retained for analysis, whereas
the remaining supernatant was centrifuged for 1 h at 100,0003 g
and 4 °C. The resulting high-speed supernatant (FS) was trans-
ferred into a new tube and the high-speed pellet (FP) mixed with
1 volume of reducing Laemmli buffer.
Heat denaturation
For heat denaturation, low-speed supernatant (S) from the
above-mentionedTris extraction, was boiled for either 5 or 30min
at 95 °C and the reaction stopped by transfer to ice. The boiled
mixture was subjected to centrifugation at 16,0003 g for 5 min to
separate supernatant fraction (HS, which is heat-stable) fromheat-
pelleted fraction (HP) and the latter was suspended with 1 volume
of reducing Laemmli buffer. The protein concentration of all frac-
tionswas determined using the Bradfordmethod.
One-dimensional electrophoresis
Samples derived from urea extraction, detergent extraction,
heat denaturation, and subcellular fractionation were subjected
to Tricine or glycine one-dimensional electrophoresis. Loading
details are given in the legends of Figs. 5–10. The Tricine gels
(10%) were run using a discontinuous buffer. The cathode
buffer consisted of 100 mM Tris, 100 mM Tricine, and 1% (w/v)
SDS and the anode buffer contained 100 mM Tris and 0.07%
(v/v) HCl. The glycine gels (10% gels or commercial gradient
gels from 4–15 or 4–20%, Bio-Rad Laboratories, USA) were
run in Tris glycine buffer containing 192 mM glycine, 25 mM
Tris, and 0.9% (w/v) SDS.
MS compatible silver staining
Gels were fixed overnight in 50% (v/v) ethanol, 10% (v/v) acetic
acid and thereafter silver stained according to standard proce-
dures (86). Briefly, gels were rinsed for 10 min in 20% (v/v) etha-
nol, incubated for 1 min in 0.02% (w/v) sodium thiosulfate solu-
tion, and rinsed twice in water. Then gels were incubated for 30
min in 0.1% (w/v) silver nitrate solution, rinsed for 1 min in water
followed by 3-6 min incubation in developing solution (2.5%
(w/v) sodium carbonate, 0.02% (v/v) formaldehyde, 0.025% (w/v)
thimerosal). The reaction was stopped by 23 10 min incubation
in 1.85% (w/v) EDTA disodium salt dihydrate, Titration complex
III. These gels were used to excise spots forMS analysis.
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Protein immunoblotting
Proteins from glycine gels were transferred to polyvinylidene
difluoride membranes at Uconst = 5 V in Towbin transfer
buffer (25 mM Tris, 200 mM glycine, 0.1% (w/v) SDS, and
20% (v/v) ethanol) for 30 min, whereas proteins from tricine
electrophoresis were transferred to polyvinylidene difluoride
at 4 °C and Iconst = 0.4 mA/cm
2 in tricine transfer buffer (300
mM tricine, 6% (v/v) acetic acid, pH 8.6) overnight. Afterward,
membranes were blocked for 1 h in blocking solution (4%
(w/v) BSA in TBS with 0.2% (v/v) Tween-20), incubated over-
night at 4 °C in primary antibody, diluted in blocking solution,
washed 3 times in TBS-T (TBS with 0.2% (v/v) Tween-20), and
incubated for 1 h in secondary antibody (Dako, Denmark),
diluted 1:5,000 in blocking solution. After washing 3 more
times in TBS-T, membranes were overlaid with ECL solution
(100 mM Tris, pH 8.5, 1.25 mM luminol, 200 mM p-coumaric
acid, 0.01% (v/v) H2O2) and chemiluminescence signals were
detected on hyper-films (GE Healthcare, USA) or by the
ChemiDoc Imaging System (Bio-Rad Laboratories, USA). All
incubations were conducted at room temperature, unless oth-
erwise stated. The antibodies tested were mAb 7/51, HT7,
Tau46, b-actin, SNAP25, synapsin-1, syntaxin-1, and PSD95
and details are given in Table 1. A tau ladder (T7951, Sigma,
USA) comprising all six human tau isoforms was included as
control for anti-tau immunoreactivity. Signals were densito-
metrically quantified using the AlphaEase software version
3.1.2 (Alpha Innotech Corporation, USA) or Image Laboratory
software version 5.0 (Bio-Rad Laboratories, USA) and values
plotted as group mean 6 S.E., without intention to perform
statistical analyses.
MS analysis and protein identification criteria
Spots of interest were excised from silver-stained gels and
excised gel bands were prepared for enzymatic cleavage by 3
times swelling/shrinking in 100 mM aqueous tetraethylammo-
nium bicarbonate solution or 50 mM tetraethylammonium bi-
carbonate in 60% acetonitrile, respectively. For reduction and
alkylation of cysteine residues, the bands were treated with tris
(2-carboxyethyl)phosphine (5 mM final) and iodoacetamide (5
mM final) during consecutive swelling steps. Each step was car-
ried out for 30 min at room temperature. After the last shrink-
ing step, the gel slices were dried for 5 min in open Eppendorf
tubes. Proteolysis was conducted by addition of trypsin or ther-
molysin (200 ng/spot) and overnight incubation at 37 °C. The
resulting peptides were acidified with formic acid (0.5% (v/v)
final concentration) prior to mass spectrometric analysis. Pep-
tides were analyzed by nanoLC-ESI-MS/MS. The LC–MS sys-
tem consisted of an Agilent 1100 nanoHPLC system (Agilent,
Germany), a PicoTip electrospray emitter (New Objective,
USA) and an Orbitrap XL mass spectrometer (ThermoFisher,
Bremen, Germany). After trapping and desalting the peptides
on a Zorbax 300SB-C18 enrichment column (0.3 mm3 5 mm,
Agilent, Germany) for 5 min using 0.5% (v/v) formic acid
solution, peptides were separated on a Zorbax 300-SB-C18 col-
umn (75mM3 150mm,Agilent, Germany) within 35min using
an acetonitrile, 0.1% formic acid gradient from 15 to 40% aceto-
nitrile. The Orbitrap instrument was operated in a data-de-
pendent mode by subjecting the 10 most abundant ions of each
survey spectrum (nominal resolution 35,000) to CID fragmen-
tation, with a normalized collision energy set at 35%. MGF files
were generated by DTA SuperCharge (version 2.0, RRID:SCR_
019206) and theMS/MSMascot search engine version 2.2 (Ma-
trix Science, UK) was used for protein identification. A custom
protein database was used comprising a complete UniProtKB
Mus musculus protein database (with 24728 entries, down-
loaded from RRID:SCR_002380 on December 2015), into
which we introduced the 6 human WT tau isoforms Tau-A to
Tau-F (downloaded from RRID:SCR_002380 on December
2015) and the mutant tau isoform from L66 mice, named Tau-
X (equivalent to Tau-F (2R4N) with the addition of P301S and
G335D mutations). The following search parameters for Mas-
cot were used and no additional threshold was applied (all sig-
nificant hits with p, 0.05 were considered): (i) instrument: ion
trap: (ii) enzyme: trypsin and thermolysin, 2 missed cleavages
allowed; (iii) variable modifications: acetyl (N-term), oxidation
(M), and deamidation (NQ); (iv) fixed modifications: carbami-
domethyl (C); (v) mass values: monoisotopic; (vi) fragment
search tolerance: 2 ppm for peptide mass and 0.5 Da; (vii) pep-
tide charge: 11, 21 and 31. For identification of phosphoryl-
ated Tau-X species, PEAKS software (version 8.0, Bioinfor-
matics Solutions Inc.) was used with the following settings:
variable modifications: carbamidomethylation, propionamide,
oxidation (M), deamidation (NQ), and phosphorylation (STY),
precursor ion tolerance: 3 ppm, fragment ion tolerance: 0.6 Da,
peptide hit threshold (210 logP) 20.0, FDR, 0.1% (FDRwas
calculated by the decoy fusion method as described in Zhang
(87)), andmaximum number of PTMs: 5.
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